
-
Spero Therapeutics NASDAQ:SPRO Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.
Location: 675 Massachusetts Ave Ste 14, Massachusetts, 02139-3309, US | Website: sperotherapeutics.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-8.053M
Cash
52.89M
Avg Qtr Burn
-5.861M
Short % of Float
1.91%
Insider Ownership
23.86%
Institutional Own.
24.23%
Qtr Updated
12/31/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tebipenem HBr (previously SPR994): oral carbapenem Details Bacterial infection, Urinary tract infection | Phase 3 Data readout | |
SPR720 Details Bacterial infection, Lung disease | Phase 2a Data readout | |
SPR206 Details Lung disease, Bacterial infection | Failed Discontinued |